RT Journal Article
SR Electronic
T1 Trial of ganglioside GM1 in acute stroke.
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP 1213
OP 1214
DO 10.1136/jnnp.51.9.1213
VO 51
IS 9
A1 B I Hoffbrand
A1 P J Bingley
A1 S M Oppenheimer
A1 C D Sheldon
YR 1988
UL http://jnnp.bmj.com/content/51/9/1213.abstract
AB Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was small the findings are believed to indicate that GM1 is unlikely to be of value in the treatment of acute stroke in the dose and route of administration used.